Picture of MaxCyte logo

MXCT MaxCyte News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapNeutral

MaxCyte Inc expected to post a loss of 13 cents a share - Earnings Preview

* MaxCyte Inc  MXCT.OQ   MXCT.O  is expected to show a fall
in
quarterly revenue when it reports  results on August 6 for the
period ending June 30 2024
    * The Rockville Maryland-based  company is expected to
report a
12.4% decrease in revenue to $7.923 million from $9.04 million a
year ago, according to the mean estimate from 6 analysts, based
on LSEG data.
    * ​LSEG's mean analyst estimate for MaxCyte Inc is for a
loss
of 13 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for MaxCyte Inc
is
$9.50​, above​ its last closing price of $4.57. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.13       -0.13      -0.09     Beat    30.8
 Dec. 31 2024  -0.07       -0.07      -0.05     Beat    30.6
 Sep. 30 2023  -0.10       -0.10      -0.11     Missed  -7.8​
 Jan. 1 0001   -0.10       -0.10      -0.10     Met     -4.2
 ​​Mar.        -0.11       -0.11      -0.11     Met     28.6
 31 2023                                                
 Jan. 1 0001               -0.07      -0.05     Beat    28.6​
 Sep. 30 2022  -0.09       -0.08      -0.06     Beat    26.8
 Jan. 1 0001   -0.09       -0.08      -0.08     Met     0
 This summary was machine generated August 2 at 22:33 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on MaxCyte

See all news